Drugs and patents in ATC class A02BA - H2-receptor antagonists

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
TAGAMET HB 200	cimetidine
CIMETIDINE	cimetidine
TAGAMET	cimetidine
TAGAMET HB	cimetidine
CIMETIDINE HYDROCHLORIDE	cimetidine hydrochloride
>Tradename	>Generic Name

Last updated: July 30, 2026

The A02BA H2-receptor antagonists market is dominated by off-patent, small-molecule brands with aging patent estates and a mature generic supply chain. Near-term value pools track specific line extensions: different salt forms, modified-release tablets, combination products (H2 blocker plus antacid), pediatric formulations, and newer method-of-use claims tied to reflux or ulcer prevention. Patent leverage is now concentrated in (1) formulation and process patents and (2) residual regulatory exclusivities, rather than primary active-ingredient composition of matter.

Segment	Typical actives in A02BA	Current market posture (high level)	Primary IP risk driver
Value generics	Famotidine, nizatidine	Broad generic availability	Strength and coverage of formulation/process patents; Orange Book listings tied to specific NDCs
Specialty / line extensions	Famotidine modified-release; pediatric oral solids; combination products	Smaller but higher litigation sensitivity	Patent-by-NDC coverage; method-of-use claims; FDA 505(b)(2) leverage
Emerging re-entries	New salts, new delivery	Limited	Proof of non-infringement and design-around complexity

What patents protect A02BA H2-receptor antagonists (famotidine, cimetidine, nizatidine) in 2026?

Most A02BA portfolios have exhausted core composition-of-matter exclusivity for the key actives. Patent protection remaining in the ecosystem typically covers:

Formulations: controlled release, orally disintegrating, pediatric dosing, granulation/process parameters, specific tablet coatings.
Processes: crystallization and purification steps that can be tied to specific impurities.
Methods of use: prevention or treatment schedules in defined populations (for example, ulcer prophylaxis in specific clinical settings).
Packaging/combination products: co-packaged or co-formulated products with antacids or other gastroprotective agents, sometimes using 505(b)(2).

Which patent families remain most relevant for H2 blockers?

The practical “who wins” patent question for A02BA is rarely “is famotidine patented,” and more often “does the asserted patent read on the specific commercial NDC and its manufacturing process.”

Common protection zones:

Modified-release: claims can cover polymer matrices, capsule/tablet structures, or coating thickness and dissolution profiles.
Pediatric oral solids: claims can cover size, disintegration behavior, and excipient systems.
Combination products: claims may cover specific ratios, layering technology, or co-administration schedules.

Which jurisdictions matter for enforcement and market entry?

United States: Orange Book listings drive Paragraph IV strategy and district court litigation.
Europe: national validity and infringement proceedings; SPC (supplementary protection certificates) can extend substance patents, but for these actives, the SPC era is generally behind.
United Kingdom / Canada / Australia: similar “right-to-market” dynamics with distinct appeal pathways and linkage systems.

When does exclusivity expire for A02BA H2-receptor antagonists?

Featured snippet answer: For the major A02BA actives, the primary composition and associated SPC-driven exclusivities largely predate the current decade; the remaining exclusivity is line-extension specific.

Exclusivity timeline structure you should model

For each brand-NDC product, exclusivity and patents can be modeled as:

US patent term (utility patents; plus any patent term adjustment)
SPC in Europe (where applicable, typically relevant earlier)
Regulatory exclusivity:
- New chemical entity (NCE): not relevant to established actives like famotidine/nizatidine.
- New formulation exclusivities: can matter for 505(b)(2) products, but rarely block the broader generic market if not tied to widely used indications.

Why “active ingredient expiration” is the wrong KPI in A02BA

In practice, generic entry and switching depend on:

Orange Book listed patents per NDC
whether those patents are method-of-use versus formulation
whether the challenger files a Paragraph IV and triggers an injunction or 30-month stay

What is the Orange Book status of H2-receptor antagonists (A02BA) and why does it drive generic entry?

Featured snippet answer: Orange Book status is product-specific; the same active ingredient can have different listed patents across strengths, dosage forms, and manufacturers.

Orange Book listing patterns common in A02BA

Old legacy brands: Orange Book lists typically thin down over time as patents expire or are withdrawn.
Line-extended brands: Orange Book can still list formulation and process patents long after the core molecule patents end.
505(b)(2) products: can maintain a narrower set of listed patents focused on bridging formulation or clinical data.

How do Paragraph IV challenges work in A02BA?

A challenger must certify to each listed patent (ANDA with Paragraph IV).
If the brand sues within statutory timelines, the FDA grants a 30-month stay for that application, not an automatic monopoly for the entire active.

Business implication: The generic entrant’s risk is not “famotidine versus patents.” It is “challenged NDC versus the asserted patents,” plus the likely settlement economics (entry date plus design-around concessions).

How strong is the patent estate for famotidine and nizatidine?

Featured snippet answer: Patent strength is mostly concentrated in formulation/process families for specific dosage forms (especially modified release) rather than composition-of-matter.

Typical strength characteristics

Formulation/process patents: can be strong if they claim specific dissolution behavior, coating compositions, or manufacturing steps that are hard to design around.
Method-of-use patents: can be weaker if claims require specific clinical predicates that generics can route around through label changes or carve-outs.
Old families: often vulnerable to invalidity challenges due to earlier prior art or predictable obviousness in salt/crystal and standard tablet-excipient selection.

Litigation posture trend in this class

A02BA tends to show:

limited innovation-heavy patent estates
sporadic but meaningful disputes around modified-release or pediatric lines
settlement-driven market entry, with carve-outs on certain strengths or indications

What generic entry risks exist for A02BA H2 blockers (ANDA approvals and launch scenarios)?

Featured snippet answer: The highest generic-entry risk is NDC-specific patent coverage for formulation/process patents, not the active ingredient itself.

Launch scenario matrix

Scenario	What challenger certified	What brand likely asserts	What generic outcomes look like
Full launch risk	Multiple asserted listed patents tied to the NDC	Formulation + process	Delay risk until resolution; settlement common
Partial launch risk	Only some NDCs covered by active patents	Narrow set; may pursue injunction leverage	Product still may launch at non-covered strengths/dosage forms
Design-around success	Challenger uses different excipient/coating/process	Brand must prove doctrine of equivalents or infringement	Faster resolution if claims are narrow
Label carve-out	Challenger avoids method-of-use infringement	Brand targets warning/label carve-outs	Often settlement with labeling constraints

Manufacturing/IP barriers to watch

controlled-release dissolution targets
coating systems and thickness
impurity specs tied to process claims
crystal form and polymorph characteristics (where relevant to salt forms)

What patent litigation affects H2-receptor antagonists in the US (Paragraph IV, settlements, and injunctions)?

Featured snippet answer: Litigation is usually product-specific, centered on Orange Book listed patents for dosage forms and strengths rather than broad active-ingredient coverage.

Where disputes concentrate

Modified-release famotidine: if a brand retains formulation patents, courts and parties focus on infringement of dissolution profiles and the claimed matrices/coatings.
Pediatric formulations: method-of-use and excipient system claims can generate disputes, but label changes often become part of settlement terms.
Combination products: infringement can pivot to ratios and unit-dose structure.

Typical settlement structure in mature A02BA

Common settlement elements:

an agreed launch date (often before final expiration of the last asserted patent)
a covenant not to sue on the specific product/labels
limitations on NDC strengths or dosage forms
sometimes a supply agreement tied to a “pay-for-delay” framework in the US (fact pattern dependent)

Which companies are challenging H2 blocker patents and how do they position generics?

Featured snippet answer: US generic entrants tend to target liquidated value pools in older brands first, then pivot to NDCs where formulation/process patents remain active.

Competitive positioning pattern

First movers file ANDAs with Paragraph IV certifications on listed patents.
If the brand’s patent estate is thin, generic challengers often win on validity/ non-infringement and launch.
If formulation patents are robust, settlements can produce staggered market entry across strengths.

Why this matters for investors

A02BA is not a “patent-dependent growth” story in most companies’ portfolios. The growth lever is execution against:

ANDA approval timing
label strategy and carve-outs
manufacturing scale-up for specific release profiles
litigation settlement economics

How do H2 blockers compare on patent estate and generic timelines versus PPIs (ATC A02BC)?

Featured snippet answer: A02BA is structurally earlier in the patent lifecycle; PPIs often show longer waves of formulation and method-of-use litigation tied to newer generations and line extensions.

Comparison framework

Class	Core molecule patent lifecycle	Common remaining IP	Entry timing sensitivity
A02BA H2 blockers	Mostly expired core patents	formulation/process for specific dosage forms	moderate; product-specific Orange Book listings
A02BC PPIs	Later-generation estates can persist	method-of-use, formulation, device delivery	high; multiple overlapping patent families

Bottom line: A02BA generics generally face fewer overlapping primary-molecule barriers; where barriers exist, they are narrower but can still block specific NDCs.

What formulations are protected in A02BA (immediate-release vs modified-release vs pediatric)?

Featured snippet answer: The strongest residual protection is usually around modified-release and pediatric excipient systems.

Immediate-release tablets and suspensions

Residual protection may cover:

specific excipient blends and manufacturing processes
stability and impurity profiles tied to process claims

Modified-release tablets/capsules

Residual protection can cover:

polymer matrices and dissolution-rate curves
coating systems that control release in defined pH windows
capsule/tablet design parameters linked to release kinetics

Pediatric formulations

Residual protection can cover:

particle size and disintegration performance in oral dispersible or chewable forms
excipient selection to stabilize pH-sensitive drug delivery

What method-of-use patents exist for A02BA and how do they affect labeling?

Featured snippet answer: Method-of-use patents can block or constrain generic labeling, but successful design-around is often achieved through label carve-outs and controlled claims around patient populations or ulcer indications.

Common method-of-use themes in reflux and ulcer prophylaxis

reflux symptom prevention with defined dosing intervals
ulcer prophylaxis in defined risk settings
recurrence prevention after healing

Labeling workaround logic

For A02BA, method-of-use claims often translate into:

label language changes
narrower indicated populations
absence of the patented regimen in the generic label

What patent expiration dates should be modeled for A02BA market entry?

Featured snippet answer: Model expiration at the patent-by-NDC level using Orange Book listed patents, not class-level active ingredient averages.

Modeling approach for commercial planning

Identify Orange Book listed patents tied to the targeted dosage form and strength.
For each patent:
- map patent expiration
- include any PTA and terminal disclaimers where applicable
Run “last patent standing” scenarios:
- worst case (all asserted patents survive)
- base case (some patents narrow or settle)
- best case (early dismissal or non-infringement)

Commercial dynamics: where is value in A02BA right now and which levers matter most?

Featured snippet answer: Value concentrates in brand-retained NDCs and line extensions, while broad shelf price competition dominates the rest.

Value levers

NDC-specific differentiation: modified-release and pediatric formulations that retain limited formulary positioning.
Distribution and contracting: pharmacy benefit and hospital formulary placement can create stickiness even after patent expiry.
Switching friction: modified-release profiles and dosing convenience can delay payer substitution.

Competitive landscape implications

The majority of market volume can be pressured by rapid generic substitution.
Residual premiums persist where the brand retains a differentiated dosage form plus at least partial patent/listing protection.

Key Takeaways

A02BA H2-receptor antagonists largely operate in a mature IP landscape; most primary active-ingredient patents have already expired.
Remaining enforceable leverage is typically product-specific, especially modified-release, pediatric, and certain combination formulations with Orange Book listed patents.
Generic entry risk is driven by NDC-to-patent mapping, not by class-level active ingredient patent status.
Patent litigation and settlements in A02BA usually resolve around narrow formulation/process coverage and label carve-outs, shaping which strengths and dosage forms enter earliest.

FAQs

1) Which A02BA products are most likely to still have Orange Book patents that can delay generic entry?
Modified-release and pediatric-specific NDCs with formulation/process claims are the most common remaining barriers, not immediate-release products.

2) Do H2-receptor antagonists face biosimilar risk?
No. A02BA refers to small-molecule H2 receptor antagonists, so the biosimilar framework does not apply.

3) What is the typical litigation trigger for H2 blocker generics in the US?
A Paragraph IV ANDA challenge to Orange Book listed patents for the targeted dosage form and strength, followed by brand suit within statutory deadlines.

4) Can generics design around A02BA formulation patents without changing the active ingredient?
Yes. Many outcomes hinge on excipient systems, coating and dissolution profiles, and manufacturing process steps tied to formulation/process claim language.

5) How should market entry dates be planned for A02BA launches?
Plan using the last-to-expire asserted Orange Book patent per targeted NDC, then overlay likely settlement outcomes and expected FDA and manufacturing timelines.

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
U.S. Food and Drug Administration. Paragraph IV Certification. (Accessed 2026).